Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.
Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.
Results from the SAUL study add support for the use of atezolizumab in patients with advanced urothelial or nonurothelial carcinoma of the urinary tract, including those with autoimmune disease and other comorbidities.
Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.
In patients with metastatic urothelial carcinoma treated with agents targeting programmed cell death protein 1 or its ligand, the presence of alterations in tumoral DNA damage response and repair genes is associated with better outcomes, findings indicate.
Adding ramucirumab to docetaxel significantly improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, show results from the phase III RANGE trial.
Advanced urothelial carcinoma patients who are unsuitable for platinum-based chemotherapy could benefit from first-line pembrolizumab, suggest phase II results reported at the American Society of Clinical Oncology 2017 annual meeting in Chicago, Illinois, USA.
A prespecified third analysis has confirmed initial findings of the KEYNOTE-045 trial of pembrolizumab in patients with advanced urothelial carcinoma who have progressed after platinum-based chemotherapy.
Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.